Bear,
SGLT2 seems to some serious issues.
"Increases in lower extremity amputation and fracture incidence were observed with canagliflozin in CANVAS and this needs further substantiation, though these events were not systematically captured in the EMPA-REG study."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688986/
The most common side effect of SGLT2 inhibitors include:
https://www.medicinenet.com/sglt2_inhibitors_type_2_diabetes_drug_class/article.htm#what_are_the_side_effects_of_sglt2_inhibitors?
And one more:
The most common adverse side effect to SGLT2 inhibitors appears to be genital infections, which were increased up to four-fold in clinical trials.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028052/
I don't have any ability to figure out the magnitude of any/all of these adverse side effects, but in aggregate, they sound disturbing.